Lasmiditan

Lasmiditan

Clinical data
Routes of administration	By mouth, intravenous
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide
CAS Number	439239-90-4 N
PubChem CID	11610526
IUPHAR/BPS	3928
ChemSpider	9785281 N
UNII	760I9WM792
KEGG	D10338 N
Chemical and physical data
Formula	C19H18F3N3O2
Molar mass	377.36 g/mol
3D model (Jmol)	Interactive image
SMILES CN3CCC(CC3)C(=O)c(n2)cccc2NC(=O)c1c(F)cc(F)cc1F
InChI InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) N Key:XEDHVZKDSYZQBF-UHFFFAOYSA-N N
NY (what is this?)

Lasmiditan (COL-144) is an investigational drug for the treatment of acute migraine. It is being developed by Eli Lilly and is in phase III clinical trials. It is a first-in-class "neurally acting anti-migraine agent" ditan.

Lasmiditan is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT_1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT_1B and 5-HT_1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction, although a 1998 review has found such side-effects to rarely occur in patients taking triptans.

Lasmiditan was discovered by Eli Lilly and Company and was out-licensed to CoLucid Pharmaceuticals in 2006, until CoLucid was bought by Eli Lilly in 2017 to reacquire the drug. The drug is protected by patents until 2031.

Phase II clinical trials for dose finding purposes were completed in 2007 for an intravenous form and in early 2010 for an oral form. Two separate Phase III clinical trials for the oral version are currently ongoing under special protocol agreements with the US Food and Drug Administration (FDA). Eli Lilly has stated that they intend to submit a new drug application to the FDA in early 2018.